Indicator type;Main activity, secondary activity or tool required for...;Total
Companies carrying out R&D in Biotechnology;Total;1.376
Companies carrying out R&D in Biotechnology;Main;711
Companies carrying out R&D in Biotechnology;Secondary;270
Companies carrying out R&D in Biotechnology;Tool required;395
% Companies by type of biotechnology used: Genetic Code;Total;31,4
% Companies by type of biotechnology used: Genetic Code;Main;37,1
% Companies by type of biotechnology used: Genetic Code;Secondary;28,5
% Companies by type of biotechnology used: Genetic Code;Tool required;23,3
% Companies by type of biotechnology used: Functional Units;Total;43,7
% Companies by type of biotechnology used: Functional Units;Main;50,2
% Companies by type of biotechnology used: Functional Units;Secondary;38,9
% Companies by type of biotechnology used: Functional Units;Tool required;35,3
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;22,8
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Main;26,3
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Secondary;22,6
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Tool required;16,8
% Companies by type of biotechnology used: Bioprocesses;Total;48,3
% Companies by type of biotechnology used: Bioprocesses;Main;38,7
% Companies by type of biotechnology used: Bioprocesses;Secondary;59
% Companies by type of biotechnology used: Bioprocesses;Tool required;58,2
% Companies by type of biotechnology used: Subcellular Organisms;Total;7,9
% Companies by type of biotechnology used: Subcellular Organisms;Main;10,6
% Companies by type of biotechnology used: Subcellular Organisms;Secondary;6
% Companies by type of biotechnology used: Subcellular Organisms;Tool required;4,2
% Companies by type of biotechnology used: Bioinformatics;Total;27,1
% Companies by type of biotechnology used: Bioinformatics;Main;34
% Companies by type of biotechnology used: Bioinformatics;Secondary;21,5
% Companies by type of biotechnology used: Bioinformatics;Tool required;18,7
% Companies by type of biotechnology used: Nanobiotechnology;Total;11,2
% Companies by type of biotechnology used: Nanobiotechnology;Main;14,5
% Companies by type of biotechnology used: Nanobiotechnology;Secondary;10
% Companies by type of biotechnology used: Nanobiotechnology;Tool required;6,2
% Companies by type of biotechnology used: Other;Total;17,6
% Companies by type of biotechnology used: Other;Main;19,2
% Companies by type of biotechnology used: Other;Secondary;17,3
% Companies by type of biotechnology used: Other;Tool required;15
% Companies by final application areas of biotechnology use: Human Health;Total;48
% Companies by final application areas of biotechnology use: Human Health;Main;64,5
% Companies by final application areas of biotechnology use: Human Health;Secondary;33,7
% Companies by final application areas of biotechnology use: Human Health;Tool required;28,1
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Total;16,9
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Main;17,2
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Secondary;18,2
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Tool required;15,3
% Companies by final application areas of biotechnology use: Food Products;Total;29,4
% Companies by final application areas of biotechnology use: Food Products;Main;20,1
% Companies by final application areas of biotechnology use: Food Products;Secondary;34,5
% Companies by final application areas of biotechnology use: Food Products;Tool required;42,7
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Total;25,7
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Main;21,8
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Secondary;31,3
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Tool required;28,9
% Companies by final application areas of biotechnology use: Environment;Total;18
% Companies by final application areas of biotechnology use: Environment;Main;16,2
% Companies by final application areas of biotechnology use: Environment;Secondary;24,6
% Companies by final application areas of biotechnology use: Environment;Tool required;16,8
% Companies by final application areas of biotechnology use: Industry;Total;13
% Companies by final application areas of biotechnology use: Industry;Main;11,7
% Companies by final application areas of biotechnology use: Industry;Secondary;17,2
% Companies by final application areas of biotechnology use: Industry;Tool required;12,6
R&D personnel in Biotechnology (PP);Total;17.257
R&D personnel in Biotechnology (PP);Main;9.048
R&D personnel in Biotechnology (PP);Secondary;4.028
R&D personnel in Biotechnology (PP);Tool required;4.180
R&D personnel in Biotechnology (PP): Research personnel;Total;9.195
R&D personnel in Biotechnology (PP): Research personnel;Main;5.201
R&D personnel in Biotechnology (PP): Research personnel;Secondary;2.189
R&D personnel in Biotechnology (PP): Research personnel;Tool required;1.806
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;8.061
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Main;3.847
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Secondary;1.840
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Tool required;2.375
R&D personnel in Biotechnology (PP). Women;Total;9.980
R&D personnel in Biotechnology (PP). Women;Main;5.508
R&D personnel in Biotechnology (PP). Women;Secondary;2.308
R&D personnel in Biotechnology (PP). Women;Tool required;2.164
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;5.222
R&D personnel in Biotechnology (PP). Women: Research personnel;Main;3.049
R&D personnel in Biotechnology (PP). Women: Research personnel;Secondary;1.239
R&D personnel in Biotechnology (PP). Women: Research personnel;Tool required;934
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;4.758
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Main;2.458
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Secondary;1.069
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Tool required;1.231
R&D personnel in Biotechnology (FTE);Total;12.883,4
R&D personnel in Biotechnology (FTE);Main;7.145,1
R&D personnel in Biotechnology (FTE);Secondary;2.868,7
R&D personnel in Biotechnology (FTE);Tool required;2.869,6
R&D personnel in Biotechnology (FTE): Research personnel;Total;7.103,2
R&D personnel in Biotechnology (FTE): Research personnel;Main;4.146,1
R&D personnel in Biotechnology (FTE): Research personnel;Secondary;1.664,6
R&D personnel in Biotechnology (FTE): Research personnel;Tool required;1.292,5
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;5.780,2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Main;2.999
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Secondary;1.204,1
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Tool required;1.577,1
R&D personnel in Biotechnology (FTE). Women;Total;7.600,6
R&D personnel in Biotechnology (FTE). Women;Main;4.390,4
R&D personnel in Biotechnology (FTE). Women;Secondary;1.697,6
R&D personnel in Biotechnology (FTE). Women;Tool required;1.512,6
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;4.057
R&D personnel in Biotechnology (FTE). Women: Research personnel;Main;2.442
R&D personnel in Biotechnology (FTE). Women: Research personnel;Secondary;931,4
R&D personnel in Biotechnology (FTE). Women: Research personnel;Tool required;683,6
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;3.543,7
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Main;1.948,5
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Secondary;766,2
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Tool required;829
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;1.283.346
Expenditure on internal R&D in Biotechnology (thousands of euros);Main;793.871
Expenditure on internal R&D in Biotechnology (thousands of euros);Secondary;225.886
Expenditure on internal R&D in Biotechnology (thousands of euros);Tool required;263.589
1) By type of expenditure: Current expenditure;Total;1.180.187
1) By type of expenditure: Current expenditure;Main;730.162
1) By type of expenditure: Current expenditure;Secondary;206.423
1) By type of expenditure: Current expenditure;Tool required;243.601
1.1) Labour expenditure of research personnel;Total;372.421
1.1) Labour expenditure of research personnel;Main;220.559
1.1) Labour expenditure of research personnel;Secondary;79.909
1.1) Labour expenditure of research personnel;Tool required;71.953
1.2) Labour expenditure of technical and auxiliary personnel;Total;229.734
1.2) Labour expenditure of technical and auxiliary personnel;Main;122.582
1.2) Labour expenditure of technical and auxiliary personnel;Secondary;46.028
1.2) Labour expenditure of technical and auxiliary personnel;Tool required;61.124
1.3) Other current expenditure;Total;578.032
1.3) Other current expenditure;Main;387.021
1.3) Other current expenditure;Secondary;80.486
1.3) Other current expenditure;Tool required;110.525
2) By type of expenditure: Capital expenditure;Total;103.159
2) By type of expenditure: Capital expenditure;Main;63.708
2) By type of expenditure: Capital expenditure;Secondary;19.463
2) By type of expenditure: Capital expenditure;Tool required;19.988
2.1) Land and buildings;Total;10.889
2.1) Land and buildings;Main;6.242
2.1) Land and buildings;Secondary;1.295
2.1) Land and buildings;Tool required;3.353
2.2) Equipment and tools;Total;59.204
2.2) Equipment and tools;Main;32.289
2.2) Equipment and tools;Secondary;13.987
2.2) Equipment and tools;Tool required;12.928
2.3) Acquisition of specific R&D software;Total;5.623
2.3) Acquisition of specific R&D software;Main;4.542
2.3) Acquisition of specific R&D software;Secondary;423
2.3) Acquisition of specific R&D software;Tool required;659
2.4) Other R&D-specific IP products;Total;27.442
2.4) Other R&D-specific IP products;Main;20.636
2.4) Other R&D-specific IP products;Secondary;3.758
2.4) Other R&D-specific IP products;Tool required;3.049
1.1) By origin of funds: Own funds;Total;887.527
1.1) By origin of funds: Own funds;Main;533.621
1.1) By origin of funds: Own funds;Secondary;160.796
1.1) By origin of funds: Own funds;Tool required;193.110
1.2) By origin of funds: Funds from the Business sector;Total;143.903
1.2) By origin of funds: Funds from the Business sector;Main;105.847
1.2) By origin of funds: Funds from the Business sector;Secondary;15.390
1.2) By origin of funds: Funds from the Business sector;Tool required;22.666
1.3) By origin of funds: Funds from the Public Administration sector;Total;126.546
1.3) By origin of funds: Funds from the Public Administration sector;Main;77.642
1.3) By origin of funds: Funds from the Public Administration sector;Secondary;25.443
1.3) By origin of funds: Funds from the Public Administration sector;Tool required;23.461
1.4) By origin of funds: Funds from the Higher Education sector;Total;94
1.4) By origin of funds: Funds from the Higher Education sector;Main;76
1.4) By origin of funds: Funds from the Higher Education sector;Secondary;0
1.4) By origin of funds: Funds from the Higher Education sector;Tool required;18
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;12.623
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Main;11.461
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Secondary;99
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Tool required;1.063
1.6) By origin of funds: Funds from the rest of the world;Total;112.652
1.6) By origin of funds: Funds from the rest of the world;Main;65.223
1.6) By origin of funds: Funds from the rest of the world;Secondary;24.158
1.6) By origin of funds: Funds from the rest of the world;Tool required;23.271
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;137.432
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Main;118.571
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Secondary;11.344
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Tool required;7.517
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;88.127
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Main;73.357
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Secondary;8.570
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Tool required;6.200
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;49.305
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Main;45.214
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Secondary;2.774
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Tool required;1.318
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;43,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Main;52,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Secondary;38,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Tool required;32,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;16,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Main;15,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Secondary;21,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Tool required;14,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;23,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Main;25
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Secondary;21,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Tool required;22,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;14,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Main;14,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Secondary;15,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Tool required;13,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;18,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Main;20,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Secondary;17,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Tool required;14,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;19,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Main;22,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Secondary;17,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Tool required;15,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;19,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Main;18,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Secondary;21,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Tool required;18,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;49,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Main;54,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Secondary;46,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Tool required;43,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;59,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Main;66,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Secondary;57,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Tool required;48,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;22,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Main;22,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Secondary;20,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Tool required;23,7
% Companies with international revenues related to biotechnology activities;Total;23,6
% Companies with international revenues related to biotechnology activities;Main;30,8
% Companies with international revenues related to biotechnology activities;Secondary;19,3
% Companies with international revenues related to biotechnology activities;Tool required;13,3
% Companies representing international revenues related to biotechnology activities;Total;1,5
% Companies representing international revenues related to biotechnology activities;Main;14,7
% Companies representing international revenues related to biotechnology activities;Secondary;0,4
% Companies representing international revenues related to biotechnology activities;Tool required;0,8
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Total;57,6
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Main;64,5
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Secondary;38,7
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Tool required;47,7
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Total;42,4
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Main;35,5
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Secondary;61,3
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Tool required;52,3
% International revenues related to biotechnology activities by classification: International trade in goods and services;Total;82,3
% International revenues related to biotechnology activities by classification: International trade in goods and services;Main;77,1
% International revenues related to biotechnology activities by classification: International trade in goods and services;Secondary;90,6
% International revenues related to biotechnology activities by classification: International trade in goods and services;Tool required;95,7
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;14,1
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Main;20,2
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Secondary;0,5
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Tool required;2,3
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Total;1,5
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Main;1,1
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Secondary;3,7
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Tool required;1
% International revenues related to biotechnology activities by classification: Other;Total;2,1
% International revenues related to biotechnology activities by classification: Other;Main;1,6
% International revenues related to biotechnology activities by classification: Other;Secondary;5,1
% International revenues related to biotechnology activities by classification: Other;Tool required;1